Suspended

03A Randomized, Double-blind, Equivalence Study of the Specificity of Tuberculin Purified Protein Derivative (PPD) (Aplisol®) in Comparison With a Reference Standard

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Aplisol@ PPD material

+ Reference Standard

+ Aplisol@ PPD material

Biological
Who is being recruted

Latent Infection+6

+ Actinomycetales Infections

+ Bacterial Infections and Mycoses

From 18 to 60 Years
See all eligibility criteria
How is the trial designed

Diagnostic Study

Phase 2
Interventional
Study Start: February 2013
See protocol details

Summary

Principal SponsorJHP Pharmaceuticals LLC
Study ContactArlene Lund, B.Sc.More contacts
Last updated: February 25, 2013
Sourced from a government-validated database.Claim as a partner

Study start date: February 1, 2013

Actual date on which the first participant was enrolled.

Primary: To determine if the 2 investigational products (Aplisol formulated from the new Tuberculin PPD drug substance and the reference standard PPD-S2) produce qualitatively similar responses (positive or negative) in subjects who are uninfected with M. tuberculosis (Mtb) or other mycobacteria. Secondary: To determine if the 2 investigational products have equivalent specificity for detecting subjects currently or previously infected with Mtb; To assess the tolerability of the investigational products in terms of the local and systemic reactogenicity events.

Principal SponsorJHP Pharmaceuticals LLC
Study ContactArlene Lund, B.Sc.More contacts
Last updated: February 25, 2013
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

152 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Diagnostic Study

Diagnostic studies focus on improving how we detect or confirm a disease. They test new tools or techniques that could provide faster or more accurate diagnoses.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 60 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Latent InfectionActinomycetales InfectionsBacterial Infections and MycosesBacterial InfectionsInfectionsMycobacterium InfectionsTuberculosisGram-Positive Bacterial InfectionsLatent Tuberculosis

Criteria

Inclusion Criteria: Males or nonpregnant females, age 18 to 70 years Negligible risk of manifesting a positive PPD test as evidenced by: Prior history of negative PPD test or interferon gamma release assay (IGRA) within 14 months before Screening No history of Bacillus Calmette- Guérin vaccination; or if vaccination status is uncertain, was born in the US and did not live outside the US as a child No history of Mtb or Mtb therapy (including isoniazid, rifampin, ethambutol, pyrazinamide, or streptomycin) No history of infection with atypical mycobacteria, including suspicious chest roentgenogram No history of high risk medical conditions (eg, HIV infection or other immunosuppressive conditions, severe chronic renal disease [as evidenced by a creatinine clearance < 30 ml/min], poorly controlled diabetes mellitus, silicosis, intravenous drug use, or alcohol abuse) No known close contact to a confirmed Mtb case (family or social setting) No history of living or travelling in India, China, Sub-Saharan Africa, or Southeast Asia in the past 6 months No exposure (other than casual) to high-risk environments for Mtb exposure (eg, prisons, homeless shelters); healthcare workers are allowed Exclusion Criteria: Subject is of childbearing potential and unable to use contraceptives; is planning pregnancy; is pregnant or lactating History of anaphylactic type reaction or other severe reaction to PPD in the past, including a history of blistering or sloughing Presence of conditions that may suppress TST reactivity, including: Protocol No. JHP-Aplisol-03 Confidential 04 May 2012 Page 8 of 38 Acute viral infections, including measles, mumps, chicken pox, human immunodeficiency virus (HIV1, HIV2). Mild viral syndromes are allowed. Acute bacterial infections including typhoid fever, brucellosis, typhus, leprosy, or pertussis Acute systemic fungal infection Live virus vaccinations within the past 6 weeks, including measles, mumps, polio, varicella, or FluMist® Metabolic derangements (eg, poorly controlled diabetes, Cushing syndrome, chronic renal failure [as evidenced by a creatinine clearance < 30 ml/min])

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
To confirm the response of PPD materials

Group II

Active Comparator
Determine equivalent specificity for new material compared to standard material.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

The University of Texas Health Science Center at Tyler

Tyler, United StatesOpen The University of Texas Health Science Center at Tyler in Google Maps
SuspendedOne Study Center